{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:31:22Z","timestamp":1793662282160,"version":"4.5.1"},"reference-count":100,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.critrevonc.2007.08.004","type":"journal-article","created":{"date-parts":[[2007,12,3]],"date-time":"2007-12-03T19:06:28Z","timestamp":1196708788000},"page":"172-182","source":"Crossref","is-referenced-by-count":83,"title":["Mycosis fungoides"],"prefix":"10.1016","volume":"65","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.M.","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cerroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2007.08.004_bib1","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/1047-2797(91)90025-8","article-title":"A registry-based case-control study of mycosis fungoides","volume":"1","author":"Weinstock","year":"1991","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/jnci\/81.20.1560","article-title":"Mycosis fungoides in relation to environmental exposures and immune response: a case-control study","volume":"81","author":"Whittemore","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1126\/science.1857968","article-title":"Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides","volume":"253","author":"Hall","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12363010","article-title":"Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma","volume":"107","author":"Wood","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib6","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-07-2247","article-title":"Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome","volume":"101","author":"Herne","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19810301)47:5<870::AID-CNCR2820470510>3.0.CO;2-R","article-title":"Effectiveness of once weekly total skin electron beam therapy in mycosis fungoides and Sezary syndrome","volume":"47","author":"Nisce","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib8","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/1097-0142(19850515)55:10<2426::AID-CNCR2820551021>3.0.CO;2-8","article-title":"Chromosome studies in 17 patients with the Sezary syndrome","volume":"55","author":"Johnson","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib9","doi-asserted-by":"crossref","first-page":"8101","DOI":"10.1158\/0008-5472.CAN-04-0366","article-title":"Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue","volume":"65","author":"Karenko","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/01.pas.0000153121.57515.c6","article-title":"Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients","volume":"29","author":"Massone","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2133.1993.tb03327.x","article-title":"Immunophenotypic studies in cutaneous T-cell lymphomas: clinical implications","volume":"129","author":"Ralfkiaer","year":"1993","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S0190-9622(96)90605-2","article-title":"Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses","volume":"35","author":"Harmon","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib13","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1182\/blood.V90.4.1636.1636_1636_1642","article-title":"Demonstration of frequent occurrence of clonal T cells in the peripheral blood of patients with primary cutaneous T-cell lymphoma","volume":"90","author":"Muche","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0147-0272(90)90018-L","article-title":"Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment","volume":"14","author":"Hoppe","year":"1990","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/00000372-197900110-00002","article-title":"The patch stage of mycosis fungoides. Criteria for histologic diagnosis","volume":"1","author":"Sanchez","year":"1979","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib16","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.132.11.1309","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib17","first-page":"725","article-title":"Report of the committee on staging and classification of cutaneous t-cell lymphomas","volume":"63","author":"Bunn","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib18","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/0190-9622(90)70054-L","article-title":"Sezary syndrome: diagnosis, prognosis, and critical review of treatment options","volume":"22","author":"Wieselthier","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib19","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/archderm.131.9.1003","article-title":"Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome","volume":"131","author":"Kim","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00005792-197201000-00004","article-title":"Mycosis fungoides. Survival, prognostic features, response to therapy, and autopsy findings","volume":"51","author":"Epstein","year":"1972","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib21","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1182\/blood-2002-11-3574","article-title":"Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study","volume":"102","author":"Tracey","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archderm.126.7.914","article-title":"Diagnostic imaging in the initial staging of mycosis fungoides and Sezary syndrome","volume":"126","author":"Kulin","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ajcp\/92.6.747","article-title":"Marrow involvement in cutaneous T-cell lymphoma. A clinicopathologic study of 60 cases","volume":"92","author":"Salhany","year":"1989","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib25","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/1523-1747.ep12365416","article-title":"Transformation of mycosis fungoides: T-cell receptor beta gene analysis demonstrates a common clonal origin for plaque-type mycosis fungoides and CD30+ large-cell lymphoma","volume":"101","author":"Wood","year":"1993","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib26","doi-asserted-by":"crossref","first-page":"372","DOI":"10.7326\/0003-4819-109-5-372","article-title":"Histopathologic staging at initial diagnosis of mycosis fungoides and the Sezary syndrome. Definition of three distinctive prognostic groups","volume":"109","author":"Sausville","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.0022-202x.2001.01476.x","article-title":"Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas","volume":"117","author":"Beylot-Barry","year":"2001","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1523-1747.2000.00830.x","article-title":"Detection of a peripheral blood T cell clone is an independent prognostic marker in mycosis fungoides","volume":"114","author":"Fraser-Andrews","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib29","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib30","first-page":"202","article-title":"Topical carmustine (BCNU) for patch\/plaque mycosis fungoides","volume":"13","author":"Zackheim","year":"1994","journal-title":"Semin Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib31","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/archderm.123.7.897","article-title":"PUVA treatment of erythrodermic and plaque-type mycosis fungoides. Ten-year follow-up study","volume":"123","author":"Abel","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/0190-9622(95)90241-4","article-title":"Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up","volume":"33","author":"Herrmann","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1001\/archderm.128.7.931","article-title":"Ultraviolet-B phototherapy for early stage cutaneous T-cell lymphoma","volume":"128","author":"Ramsay","year":"1992","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0190-9622(93)70155-M","article-title":"Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients","volume":"29","author":"Resnik","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib35","doi-asserted-by":"crossref","first-page":"198S","DOI":"10.1111\/1523-1747.ep12875523","article-title":"Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma","volume":"95","author":"Roenigk","year":"1990","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2005.03.012","article-title":"Narrowband ultraviolet B phototherapy to clear and maintain clearance in patients with mycosis fungoides","volume":"53","author":"Boztepe","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1067\/mjd.2002.120911","article-title":"Narrowband UVB phototherapy for early stage mycosis fungoides","volume":"47","author":"Gathers","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1067\/mjd.2003.80","article-title":"Narrowband UVB and psoralen-UVA in the treatment of early stage mycosis fungoides: a retrospective study","volume":"48","author":"Diederen","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib39","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1600-0781.2005.00183.x","article-title":"Narrow band UVB (311nm), psoralen UVB (311nm) and PUVA therapy in the treatment of early stage mycosis fungoides: a right-left comparative study","volume":"21","author":"El Mofty","year":"2005","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib40","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2230.2005.01840.x","article-title":"Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients","volume":"30","author":"Ghodsi","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib41","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0190-9622(86)70124-2","article-title":"Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation","volume":"14","author":"Wood","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0190-9622(03)00868-5","article-title":"Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma","volume":"50","author":"Coors","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib44","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"de Quatrebarbes","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib45","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream","volume":"52","author":"Deeths","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib47","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1159\/000429580","article-title":"Total skin electron beam therapy in the management of mycosis fungoides","volume":"25","author":"Hoppe","year":"1991","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib49","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0360-3016(97)00127-2","article-title":"Total skin electron beam therapy followed by adjuvant psoralen\/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides)","volume":"38","author":"Quiros","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib50","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0360-3016(94)90103-1","article-title":"Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY","volume":"28","author":"Jones","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib51","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/S0190-9622(96)90282-0","article-title":"Combined modality therapy for cutaneous T-cell lymphoma","volume":"34","author":"Duvic","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib52","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/0190-9622(92)70142-3","article-title":"Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","volume":"26","author":"Jones","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib54","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0360-3016(98)00517-3","article-title":"Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides","volume":"43","author":"Chinn","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib55","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0360-3016(95)00073-8","article-title":"Systemic chemotherapy and extracorporeal photochemotherapy for T3 and T4 cutaneous T-cell lymphoma patients who have achieved a complete response to total skin electron beam therapy","volume":"32","author":"Wilson","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib56","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.1986.4.7.1094","article-title":"Combined modality treatment of cutaneous T cell lymphoma: results of a 6-year follow-up","volume":"4","author":"Winkler","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0190-9622(92)70202-Q","article-title":"Therapeutic alternatives in cutaneous T-cell lymphoma","volume":"27","author":"Holloway","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib58","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib59","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2133.1991.tb14772.x","article-title":"The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate","volume":"125","author":"Dreno","year":"1991","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib60","first-page":"1253","article-title":"Extracorporeal photopheresis in the therapy of Sezary syndrome","volume":"134","author":"Marschalko","year":"1993","journal-title":"Orv Hetil"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib61","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in 29 patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib62","doi-asserted-by":"crossref","first-page":"592","DOI":"10.7326\/0003-4819-121-8-199410150-00007","article-title":"Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome)","volume":"121","author":"Bunn","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib63","first-page":"647","article-title":"Combination chemotherapy for mycosis fungoides: a southwest oncology group study","volume":"63","author":"Grozea","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0889-8588(18)30061-3","article-title":"Chemotherapy for mycosis fungoides and the Sezary syndrome","volume":"9","author":"Rosen","year":"1995","journal-title":"Hematol Oncol Clin N Am"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib65","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2133.2004.05712.x","article-title":"Treatment of advanced mycosis fungoides\/Sezary syndrome with fludarabine and potential adjunctive benefit to subsequent extracorporeal photochemotherapy","volume":"150","author":"Quaglino","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib66","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/ajcp\/102.6.856","article-title":"Flow cytometric detection of neoplastic T cells in patients with mycosis fungoides based on levels of T-cell receptor expression","volume":"102","author":"Kuchnio","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib67","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/jnci\/82.16.1353","article-title":"Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a southwest oncology group study","volume":"82","author":"Von Hoff","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib69","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1992.10.12.1907","article-title":"Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides\/Sezary syndrome","volume":"10","author":"Foss","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib70","first-page":"133","article-title":"Autologous bone marrow transplantation for advanced stage mycosis fungoides","volume":"7","author":"Bigler","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib71","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archderm.138.10.1359","article-title":"Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma","volume":"138","author":"Guitart","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib72","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mjd.2002.122188","article-title":"Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Masood","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib73","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib74","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib75","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/sj.bmt.1703872","article-title":"Treatment of advanced mycosis fungoides by allogeneic stem-cell transplantation with a nonmyeloablative regimen","volume":"31","author":"Soligo","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib76","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V77.1.20.20","article-title":"Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides","volume":"77","author":"Knox","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib77","first-page":"106","article-title":"All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi)","volume":"82","author":"Sacchi","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib78","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II\u2013III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib79","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib80","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1200\/JCO.1998.16.10.3257","article-title":"CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-hodgkin's lymphoma","volume":"16","author":"Lundin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib81","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1385\/MO:18:2:99","article-title":"Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders","volume":"18","author":"Pangalis","year":"2001","journal-title":"Med Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.critrevonc.2007.08.004_bib83","first-page":"85","article-title":"Phase 2 study of alemtuzumab (Campath-1H) in patients with advanced mycosis fungoides\/S\u00e8zary syndrome","volume":"13","author":"Hagberg","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib84","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib85","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib86","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib87","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2004-01-0360","article-title":"Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas","volume":"104","author":"Dummer","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib88","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1182\/blood-2002-08-2455","article-title":"Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells","volume":"102","author":"Maier","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib89","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib90","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/cncr.21449","article-title":"Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients","volume":"104","author":"Marchi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib91","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib92","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaad.2003.05.009","article-title":"Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas","volume":"51","author":"Tsimberidou","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib94","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0889-8588(03)00109-6","article-title":"Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2","volume":"17","author":"Rook","year":"2003","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib95","first-page":"179a","article-title":"Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL) [abstract]","volume":"102","author":"Duvic","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib96","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1182\/blood-2004-03-1190","article-title":"Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15","volume":"104","author":"Wysocka","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib97","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib98","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1182\/blood-2006-05-021873","article-title":"Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias","volume":"109","author":"Gojo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib99","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1093\/annonc\/mdh438","article-title":"A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine","volume":"15","author":"Undevia","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2007.08.004_bib100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-05-1423","article-title":"Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)","volume":"12","author":"Robey","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842807001813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T03:17:50Z","timestamp":1588130270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842807001813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S1040842807001813"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2007.08.004","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}